Estrella Immunopharma, Inc. (ESLAW)
↓ Download CSV| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Income | -$13.06M | -$7.31M | -$11.11M | -$1.57M | -$249.1K |
| Net Income | -$13.06M | -$7.31M | -$11.11M | -$996.1K | -$247.7K |
| EPS (Diluted) | $-0.35 | $-0.27 | $-36.35 | — | — |
| Total Assets | $3.18M | $3.14M | $3.03M | $9.72M | $45.80M |
| Total Liabilities | $13.54M | $3.00M | $9.77M | $2.65M | $1.62M |
| Shareholders' Equity | -$10.37M | $143.7K | -$11.74M | -$2.26M | -$1.01M |
| Cash & Equivalents | $1.38M | $916.9K | $2.48M | $40.8K | $478.9K |
| Operating Cash Flow | -$1.79M | -$16.07M | -$1.34M | -$1.04M | -$316.2K |
| Shares Outstanding | 36.82M | 27.10M | 305.7K | — | 1.18M |